lifestyle.forkstofeet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NEKTAR THERAPEUTICS
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
March 28, 2026
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
March 20, 2026
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 12, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2026
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
February 26, 2026
Nektar Therapeutics to Participate in Two Investor Conferences in March
February 24, 2026
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
February 17, 2026
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 14, 2026
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
February 13, 2026
Nektar Therapeutics Announces Proposed Public Offering
February 13, 2026
1
2
Next Page
→